Chronic myeloid leukemia: a minimalistic view of post-therapeutic monitoring.

摘要: A variety of molecular-based targets are potentially amenable to analysis for the evaluation minimal residual disease (MRD) following attempts at curative therapies in hematological malignancies. These can be broadly divided into one three types: pathological rearrangements (translocations), physiological (antigen receptor gene rearrangements), and others (for example overexpression Wilm’s tumor WT1). This review will focus on specific extensively studied from first group, namely t(9;22) chronic myeloid leukemia (CML). Any appreciation MRD testing is contingent an understanding biology being tested, as well therapeutic scenario which it tested. Accordingly, this article also briefly both therapy CML. The reader referred a number recent reviews that cover other molecular available testing, 1, 2, 3 excellent specifically addressing 4, 5, 6